Skip to main content

Table 2 Change in evaluated clinical outcome measures after treatment

From: Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA

  All sample (N = 395) Respondersa (N = 194) No responders (N = 201) P-value
Headache days/month −11.3 ± 10.7 −15.3 ± 10.2 −7.4 ± 7.3 < 0.0001
Moderate-severe headache days/month −7.3 ± 7.0 −8.5 ± 8.9 −3.6 ± 8.1 < 0.0001
≥50% headache days rate 51.4% 66.5% 36.8% < 0.0001
≥50% moderate-severe headache days rate 54.2% 70.6% 38.3% < 0.0001
Conversion to episodic migraine 52.9% 68.0% 38.3% < 0.0001
≥50% pain intensity reduction 35.8% 50.0% 21.0% < 0.0001
Acute treatment use (pills/month) −24.9 ± 26.5 −34.2 ± 52.7 −14.1 ± 37.9 < 0.0001
≥50% acute treatment reduction (pills/month) 60.4% 69.6% 49.3% < 0.0001
Conversion from medication overuse to non-medication overuse 37.5% 44.8% 30.3% 0.004
≥50% MIDAS score reduction rate 49.1% NA NA NA
  1. aResponders were patients who presented a ≥ 50% improvement in MIDAS score after two cycles of OnabotulinumtoxinA. †P-values are assessed between responders and non-responders. Unpaired t-test were used for quantitative variables and Pearson’s Chi-squared test with Yate’s continuity correction for dichotomous variables
\